Skip to main content

Accelrys to Acquire Synomics

NEW YORK, June 21 - Accelrys announced it will acquire Synomics in a stock transaction valued at $4 million, the companies announced Thursday.

Accelrys, based in San Diego and Cambridge, UK, and a subsidiary of Pharmacopeia of Princeton, NJ, agreed to acquire all outstanding stock of privately-held Synomics. The companies believe the transaction will be completed within several days. 

"The acquisition of Synomics marks another significant step towards the development by Accelrys of a comprehensive, integrated software platform for research and development," Michael Stapleton, chief operating officer of Accelrys, said in a statement. "In addition to strengthening our strategic technology position, the acquisition will provide us with 40 highly qualified staff who will be quickly integrated, primarily into our new consulting organization."

Stapleton added that the acquisition may "slightly dilute" Accelry's earnings for the remainder of 2001 as the company integrates Synomics software into its own technology and its sales and marketing network.

Synomics, a developer of enterprise-wide software systems, is based in Cambridge, UK.

Accelrys was formed in April when Pharmacopeia merged its software subsidiaries. 

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.